.jpeg)
Pegcetacoplan (Empaveli): Complete Guide to PNH Complement Inhibitor Treatment
1. Drug Overview
Pegcetacoplan, brand name Empaveli, is a complement inhibitor primarily used for treating adult paroxysmal nocturnal hemoglobinuria (PNH). Developed by Apellis Pharmaceuticals, this medication provides new treatment options for PNH patients.
2. Mechanism of Action
Pegcetacoplan is a PEGylated complement C3 inhibitor that binds to complement C3, preventing its cleavage into C3a and C3b, thereby inhibiting activation of all complement pathways. This mechanism enables comprehensive control of complement-mediated hemolytic reactions.
3. Comparison with Traditional Drugs
Compared to eculizumab, pegcetacoplan provides more comprehensive inhibition of complement activation. Eculizumab only inhibits the terminal end of the complement cascade (C5 inhibitor), while pegcetacoplan acts further upstream, preventing both intravascular and extravascular hemolysis.
4. Main Indications
Pegcetacoplan is primarily used for treating adult paroxysmal nocturnal hemoglobinuria (PNH). It is suitable for patients who have received eculizumab treatment but still have anemia, and can also serve as an initial treatment option.
5. Domestic Market Availability
Pegcetacoplan is not yet available in the domestic market. Patients need to obtain relevant information through special channels.
6. International Market Pricing
In overseas markets, pegcetacoplan is available in 1080mg/20ml specification, priced at approximately four thousand US dollars. Specific prices vary by region, specification, and procurement channels.
7. Clinical Efficacy
Pegcetacoplan demonstrates good efficacy in treating PNH. Clinical studies show that compared to eculizumab, pegcetacoplan can more significantly improve anemia and reduce transfusion requirements.
8. Safety Analysis
Common adverse reactions include injection site reactions, fever, headache, and back pain. Most adverse reactions are mild to moderate. Serious adverse reactions may include infections, particularly increased risk of meningococcal infection, requiring close monitoring during use.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
